Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
Latest Information Update: 05 Mar 2025
Price :
$35 *
At a glance
- Drugs Ziltivekimab (Primary)
- Indications Heart failure; Inflammation
- Focus Registrational; Therapeutic Use
- Acronyms ATHENA
- Sponsors Novo Nordisk
- 03 Jan 2025 Planned End Date changed from 10 Sep 2026 to 12 Jan 2027.
- 03 Jan 2025 Planned primary completion date changed from 3 Jun 2026 to 5 Oct 2026.
- 22 Aug 2024 Planned End Date changed from 17 Aug 2026 to 10 Sep 2026.